Editas

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Exclusive Sharon Begley

CRISPR patent fight: The legal bills are soaring

In the Lab Sharon Begley

First bid to use CRISPR to edit human genes up for federal review

Business Damian Garde

After rivals’ IPOs, will CRISPR Therapeutics go public or stay buttoned-down?

Business Robert Weisman — Boston Globe

Editas Medicine raises $94.4 million in year’s first IPO

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: new Valeant CEO, success for Eli Lilly diabetes treatment

Business Sharon Begley

Advances in gene editing, and hype, underlie Editas move to go public